PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025
Report Description The colorectal cancer (CRC) market considering the sales of both branded treatments and generic chemotherapy is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence and the launch and uptake of premium-priced therapies. Traditionally the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However the efficacy of these agents is limited by the insurgence of acquired resistance. Further RAS mutant patients who are not eligible to EGFR inhibitors have a lower number of available treatment options and usually receive fewer lines of treatment compared with patients with RAS wild-type disease. The CRC competitive landscape is going to experience a substantial change following the approval of pipeline agents exploiting novel mechanisms of actions especially immunotherapy
Continued‌
Scope - Overview of CRC including epidemiology etiology pathophysiology symptoms diagnosis and treatment guidelines. - Annualized CRC therapeutics market revenue cost of therapy and treatment usage pattern data in 8 patient segments forecast from 2015 to 2025. - Key topics covered include strategic competitor assessment market characterization unmet needs clinical trial mapping and implications for the CRC therapeutics market.
Download FREE REPORT Sample @
https://www.24marketreports.com/request-sample/pharm
Table of Contents 1 Table of Contents 9 1.1 List of Tables 16 1.2 List of Figures 22 2 Introduction 25 2.1 Catalyst 25 2.2 Related Reports 26 2.3 Upcoming Related Reports 26 3 Disease Overview 27 3.1 Etiology and Pathophysiology 27 3.2 Clinical Staging 32 3.3 Symptoms 34
Visit us at : https://www.24marketreports.com/life-sciences/pharmapoin t-colorectal-cancer---global-drug-forecast-and-market-an alysis-to-2025
Stay With Us :
Int'l: (+1) 646 781 7170 Email: help@24marketreports.com
New York City Zone 01, NY, United States.